专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006126066A3 A RECOMBINANT METHOD FOR PRODUCTION OF AN ERYTHROPOIESIS STIMULATING PROTEIN 审中-公开
标题翻译：一种用于生产红细胞生成素刺激蛋白的重组方法
公开(公告)号：WO2006126066A3
公开(公告)日：2007-07-12
申请号：PCT/IB2006001353
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD , MORAWALA PATELL VILLOO
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K14/505
CPC分类号： C07K14/505 , A61K38/00
摘要： The present invention relates to the recombinant method used for the production of a highly glycosylated form (in total five N linked glycosylations as opposed to three N linked glyosylations in the natural EPO) of erythropoietin. The added sites for glycosylation will result in greater number of carbohydrate chains, and higher sialic acid content than human EPO, which in turn would impart to the recombinant molecule a longer half-life. The invention further relates to the construction of expression cassettes comprising nucleic acid sequences encoding for the highly glycosylated form of Erythropoietin and stable expression in the host cells. The invention further relates to the optimized method for purification of the erythropoiesis stimulating protein. The recombinant EPO according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for an increase in the hematocrit for treatment of anemia and for restoration of patient well being and quality of life.
摘要翻译：本发明涉及用于生产高度糖基化形式（在天然EPO中与三个N连接的糖基化相反的总共5个N连接的糖基化）促红细胞生成素的重组方法。糖基化的添加位点将导致比人EPO更多的碳水化合物链和更高的唾液酸含量，其又赋予重组分子更长的半衰期。本发明还涉及包含编码高糖基化形式的红细胞生成素的核酸序列并在宿主细胞中稳定表达的表达盒的构建。本发明还涉及促红细胞生成蛋白的纯化的优化方法。根据本发明的重组EPO及其盐和功能衍生物可以包含药物组合物的活性成分，用于增加用于治疗贫血的血细胞比容和恢复患者的生活质量和生活质量。

2. 发明申请

WO2006126069A3 A METHOD FOR THE PRODUCTION OF A MONOCLONAL ANTIBODY TO CD20 FOR THE TREATMENT OF B-CELL LYMPHOMA 审中-公开
标题翻译：用于生产CD20单克隆抗体以治疗B细胞淋巴瘤的方法
公开(公告)号：WO2006126069A3
公开(公告)日：2007-10-04
申请号：PCT/IB2006001358
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD , MORAWALA PATELL VILLOO
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K16/28
CPC分类号： C07K16/2887 , C07K2317/24
摘要： The present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). The treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.
摘要翻译：本发明涉及用于生产结合CD20的抗体可溶形式的重组方法，用于治疗复发性或难治性，低级或滤泡型CD20阳性，B细胞非霍奇金淋巴瘤（NHL）的患者）。治疗将包括使用免疫活性的抗CD20抗体; 或放射性标记的抗CD20抗体和/或协同策略，其中标记和未标记的抗体将用于治疗NHL。该方法描述了编码抗CD20的核酸序列的从头合成，将构建的核酸序列转化为感受态细菌，并将其亚克隆至用于表达所需蛋白质的哺乳动物表达载体中。已经公开了包含与感兴趣的基因相关的对照元件的DNA构建体。感兴趣的核酸序列已被密码子优化以允许在合适的哺乳动物宿主细胞中表达。

3. 发明专利

AU2012202462A1 Novel efficient transformation method for sunflower and oil seeds based on positive selection 未知
公开(公告)号：AU2012202462A1
公开(公告)日：2012-05-17
申请号：AU2012202462
申请日：2012-04-27
申请人： AVESTHA GENGRAINE TECH PVT LTD
发明人： MORAWALA PATELL VILLOO , RAJYASHRI K R
IPC分类号： C12N15/82 , C12N9/92 , C12N15/61
摘要： The invention describes a highly improved, reproducible and a consistent method of transformation and regeneration that results in obtaining 12-15% transgenic plants. The present invention relates to a method of selecting genetically transfonned Sunflower explants based on their ability to utilize Xylose as a sole carbohydrate source. Further disclosed is the nucleic acid sequence of the Xylose Isomerase gene, vector construction for incorporation of the selection marker gene and the process of Agrobacterium Mediated Transformation of target host plant with the vector comprising the gene encoding the enzyme Xylose isomerase under the functional combination of the heterologous regulatory sequences. Also disclosed is the method of selecting the putative transfonnants post tTansformation with the said vector that possess a metabolic advantage of utilizing Xylose as a sole carbon source. Increased efficiency of regeneration, better growth and survival has been observed on subjection to the described method of positive selection. The subject invention alleviates the disadvantages of negative selection methods such as the undesired elimination of the transformed cells and the potential. environmental harm caused due to the dispersal of the antibiotic and the herbicide resistant genes. Presence of the complete Xylose isomerase domain in the -5kb sequence of SC-1 desaturase SUBSTITUTE SHEET (RULE 26)

4. 发明专利

BRPI0611405A2 未知
公开(公告)号：BRPI0611405A2
公开(公告)日：2010-09-08
申请号：BRPI0611405
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K14/505
摘要： The present invention relates to the recombinant method used for the production of a highly glycosylated form (in total five N linked glycosylations as opposed to three N linked glyosylations in the natural EPO) of erythropoietin. The added sites for glycosylation will result in greater number of carbohydrate chains, and higher sialic acid content than human EPO, which in turn would impart to the recombinant molecule a longer half-life. The invention further relates to the construction of expression cassettes comprising nucleic acid sequences encoding for the highly glycosylated form of Erythropoietin and stable expression in the host cells. The invention further relates to the optimized method for purification of the erythropoiesis stimulating protein. The recombinant EPO according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for an increase in the hematocrit for treatment of anemia and for restoration of patient well being and quality of life.

5. 发明专利

AU2006250888A1 A method for the production of a monoclonal antibody to CD20 for the treatment of B-cell lymphoma 未知
公开(公告)号：AU2006250888A1
公开(公告)日：2006-11-30
申请号：AU2006250888
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K16/28
摘要： The present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). The treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.

6. 发明专利

AU2006334508A1 Novel efficient transformation method for sunflower and oil seeds based on positive selection 未知
公开(公告)号：AU2006334508A1
公开(公告)日：2007-07-19
申请号：AU2006334508
申请日：2006-01-12
申请人： AVESTHA GENGRAINE TECH PVT LTD
发明人： MORAWALA PATELL VILLOO , RAJYASHRI K R
IPC分类号： C12N15/82 , C12N9/92 , C12N15/61
摘要： The invention describes a highly improved, reproducible and a consistent method of transformation and regeneration that results in obtaining 12-15% transgenic plants. The present invention relates to a method of selecting genetically transformed Sunflower explants based on their ability to utilize Xylose as a sole carbohydrate source. Further disclosed is the nucleic acid sequence of the Xylose Isomerase gene, vector construction for incorporation of the selection marker gene and the process of Agrobacterium Mediated Transformation of target host plant with the vector comprising the gene encoding the enzyme Xylose isomerase under the functional combination of the heterologous regulatory sequences. Also disclosed is the method of selecting the putative transformants post transformation with the said vector that possess a metabolic advantage of utilizing Xylose as a sole carbon source. Increased efficiency of regeneration, better growth and survival has been observed on subjection to the described method of positive selection. The subject invention alleviates the disadvantages of negative selection methods such as the undesired elimination of the transformed cells and the potential environmental harm caused due to the dispersal of the antibiotic and the herbicide resistant genes.

7. 发明专利

CA2609480A1 RECOMBINANT METHOD FOR THE PRODUCTION OF A MONOCLONAL ANTIBODY TO CD52 FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA 未知
公开(公告)号：CA2609480A1
公开(公告)日：2006-11-30
申请号：CA2609480
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K16/28 , A61K39/395
摘要： The present invention relates to the recombinant method used for the production of soluble form monoclonal antibody that binds to CD52. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD 52, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.

8. 发明专利

CA2609731A1 A METHOD FOR THE PRODUCTION OF A MONOCLONAL ANTIBODY TO CD20 FOR THE TREATMENT OF B-CELL LYMPHOMA 未知
公开(公告)号：CA2609731A1
公开(公告)日：2006-11-30
申请号：CA2609731
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K16/28
摘要： The present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). The treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub- cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.

9. 发明专利

CA2609473A1 A RECOMBINANT METHOD FOR PRODUCTION OF AN ERYTHROPOIESIS STIMULATING PROTEIN 未知
公开(公告)号：CA2609473A1
公开(公告)日：2006-11-30
申请号：CA2609473
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K14/505
摘要： The present invention relates to the recombinant method used for the production of a highly glycosylated form (in total five N linked glycosylations as opposed to three N linked glyosylations in the natural EPO) of erythropoietin. The added sites for glycosylation will result in greater number of carbohydrate chains, and higher sialic acid content than human EPO, which in turn would impart to the recombinant molecule a longer half-life. The invention further relates to the construction of expression cassettes comprising nucleic acid sequences encoding for the highly glycosylated form of Erythropoietin and stable expression in the host cells. The invention further relates to the optimized method for purification of the erythropoiesis stimulating protein. The recombinant EPO according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for an increase in the hematocrit for treatment of anemia and for restoration of patient well being and quality of life.

10. 发明专利

MX2007014673A METODO PARA LA PRODUCCION DE UN ANTICUERPO MONOCLONAL PARA CD20 PARA EL TRATAMIENTO DE LINFOMA DE CELULAR B. 未知
公开(公告)号：MX2007014673A
公开(公告)日：2008-04-08
申请号：MX2007014673
申请日：2006-05-24
申请人： AVESTHA GENGRAINE TECH PVT LTD
发明人： MORAWALA PATELL VILLOO
IPC分类号： C07K16/28
摘要： La presente invencion se refiere al metodo recombinante utilizado para la produccion de forma soluble de un anticuerpo que une a CD20 para tratamiento de pacientes con linfoma recidiva, refractaria, de grado inferior o folicular, CD20-positivo, linfoma no Hodgkin de celula B (NHL, por sus siglas en ingles). El tratamiento comprendera el uso de anticuerpos anti-CD20 activos inmunologicamente; o anticuerpos anti-CD20 marcados radiactivamente y/o estrategias cooperativas en donde ambos, los anticuerpos activados y no activados seran utilizados para el tratamiento de NHL. El procedimiento describe la sintesis de novo de la secuencia de acido nucleico que codifica anti-CD20, la transformacion de la secuencia de acido nucleico construida en la bacteria competente y la sub-clonacion del mismo en vectores de expresion del mamifero para expresion de la proteina deseada. Se muestran constructos de DNA que comprenden los elementos de control asociados con el gen de interes. La secuencia de acido nucleico de interes ha sido el codon optimizado para permitir la expresion de las celulas hospederas del mamifero apropiado.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式